LegalizeCommission Implementing Regulation (EU) 2023/1808 of 21 September 2023 setting out the template for the provision of information on prevention, preparedness and response planning in relation to serious cross-border threats to health in accordance with Regulation (EU) 2022/2371 of the European Parliament and of the Council
This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.
| 22.9.2023 | EN | Official Journal of the European Union | L 234/105 |
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) 2022/2371 of the European Parliament and of the Council of 23 November 2022 on serious cross-border threats to health and repealing Decision No 1082/2013/EU 1, and in particular Article 7(3) thereof,
Whereas:
- (1) Regulation (EU) 2022/2371 lays down mechanisms and structures for coordinating preparedness for and response to serious cross-border threats to health, including reporting on prevention, preparedness and response planning.
- (2) Pursuant to Article 7(1), first subparagraph, of Regulation (EU) 2022/2371, Member States are to provide the Commission and relevant Union agencies and bodies an updated report on prevention, preparedness and response planning and implementation at national level, and where appropriate, cross-border interregional levels by 27 December 2023 and every 3 years thereafter.
- (3) Article 7(1), second and third subparagraphs, of Regulation (EU) 2022/2371 lay down the information on prevention, preparedness and response planning which Member States are to provide to the Commission and relevant Union agencies and bodies.
- (4) Pursuant to Article 7(2)), first subparagraph, of Regulation (EU) 2022/2371, every 3 years the Commission is to make the information received available to the Health Security Committee (HSC) in a report prepared in collaboration with the European Centre for Disease Prevention and Control (ECDC) and other relevant Union agencies and bodies. That report is to include country profiles for monitoring progress and developing action plans to address gaps identified at national level for which the Commission may issue general recommendations considering the outcomes of the assessment of Article 8 of that Regulation.
- (5) Pursuant to Article 7(2), second and third subparagraphs, of Regulation (EU) 2022/2371, based on that report, the Commission is to initiate discussion in the HSC on the progress and gaps in preparedness. An overview of recommendations of the report is to be published on the websites of the Commission and the ECDC.
- (6) The template of the questionnaire to be used by Member States when providing the information referred to in Article 7(1) of that Regulation should ensure its relevance to the objectives identified in that paragraph and its comparability, while avoiding any duplication of information requested and submitted. The template was elaborated in close collaboration with the Working Group on Preparedness of the HSC with active participation of majority of Member States, the relevant Commission Directorates-General, the ECDC, and the World Health Organisation (WHO). The template was aligned, where possible, with the International Health Regulations (2005) State Party Self-Assessment Report (SPAR).
- (7) The measures provided for in this Regulation are in accordance with the opinion of the Committee on serious cross-border threats to health,
HAS ADOPTED THIS REGULATION:
Article 1
The template to be used by Member States when providing information on their prevention, preparedness and response planning in relation to serious cross-border threats to health in accordance with Article 7(1) of Regulation (EU) 2022/2371, as is set out in the Annex to this Regulation, is adopted.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 21 September 2023.
For the Commission
The President
Ursula VON DER LEYEN
ANNEX
Table of contents
| A. | International Health Regulations (IHR) 2005 capacities | 108 |
| --- | --- | --- |
| 1. | Policy, legal and normative Instruments to implement the International Health Regulations (IHR) 2005 | 108 |
| --- | --- | --- |
| 2. | Financing | 109 |
| --- | --- | --- |
| 3. | Laboratory | 110 |
| --- | --- | --- |
| 4. | Surveillance | 113 |
| --- | --- | --- |
| 5. | Human resources | 114 |
| --- | --- | --- |
| 6. | Health emergency management | 115 |
| --- | --- | |
| Management of health emergency response | 115 | |
| --- | --- | |
| Emergency logistic and supply chain management | 118 | |
| --- | --- | --- |
| 7. | Health services provision | 121 |
| --- | --- | --- |
| 8. | Risk communication | 124 |
| --- | --- | --- |
| 9. | Points of entry (PoEs) and border health | 125 |
| --- | --- | --- |
| 10. | Zoonotic diseases and threats of environmental origin, including those due to the climate | 126 |
| --- | --- | --- |
| 11. | Chemical events | 127 |
| --- | --- | --- |
| B. | Additional capacities as per Regulation (EU) 2022/2371 | 129 |
| --- | --- | --- |
| 12. | Antimicrobial resistance (AMR) and Healthcare associated infections | 129 |
| --- | --- | |
| AMR | 129 | |
| --- | --- | |
| Healthcare associated infections (HAIs) | 134 | |
| --- | --- | --- |
| 13. | Union level coordination and support functions | 135 |
| --- | --- | --- |
| 14. | Research development and evaluations to inform and accelerate emergency preparedness | 137 |
| --- | --- | --- |
| 15. | Recovery elements | 139 |
| --- | --- | --- |
| 16. | Actions taken to improve gaps found in the implementation of prevention, preparedness, and response plans | 139 |
| --- | --- | --- |
| C. | Other | 141 |
A. INTERNATIONAL HEALTH REGULATIONS (IHR) 2005 CAPACITIES
1. Policy, legal and normative Instruments to implement the International Health Regulations (IHR) 2005
| Question | Question | Indicator | |
| A.1.1 | Regarding your Member State’s legal instruments for preparedness and response planning, please indicate your Member State’s corresponding level: | Regarding your Member State’s legal instruments for preparedness and response planning, please indicate your Member State’s corresponding level: | Indicator 1-5 |
| A.1.1 | level | Indicator 1-5 | |
| A.1.1 | Legal instruments do not incorporate coordination across national, regional, and local levels of government during a public health emergency | 1 | Indicator 1-5 |
| A.1.1 | Legal instruments incorporate coordination across national, regional, and local levels of government during a public health emergency | 2 | Indicator 1-5 |
| A.1.1 | Legal instruments incorporate coordination across national, regional, and local levels of government during a public health emergency. In addition, legal instruments also incorporate coordination with sectors responsible for critical infrastructure during a public health emergency | 3 | Indicator 1-5 |
| A.1.1 | Legal instruments incorporate coordination across national, regional, and local levels of government during a public health emergency. In addition, legal instruments also incorporate coordination with sectors responsible for critical infrastructure during a public health emergency. Moreover, the operational readiness of these legal instruments has been tested in the last 3 years | 4 | Indicator 1-5 |
| A.1.1 | As per level 4 and, in addition, there is a mechanism for reviewing and revising legal instruments (if needed based on recommendations from testing) | 5 | Indicator 1-5 |
| A.1.1 | — If level 5: has your country revised the legal instruments in the last 3 years? (yes/no) — If yes, please upload relevant links (optional for Member States): — Additional comments: | — If level 5: has your country revised the legal instruments in the last 3 years? (yes/no) — If yes, please upload relevant links (optional for Member States): — Additional comments: | Indicator 1-5 |
| A.1.2 | In the event of a public health emergency, do your country’s legal instruments for IHR 2005 implementation assign a clear decision-making process, which may comprise one or more authorities? (yes/no/other) — If other, please describe: | In the event of a public health emergency, do your country’s legal instruments for IHR 2005 implementation assign a clear decision-making process, which may comprise one or more authorities? (yes/no/other) — If other, please describe: | Not applicable (N/A) |
2. Financing
| Question | Question | Indicator | |
| A.2.1 | Regarding Member States’s planning to test the financial resources for contingency funding to respond to health threats, please indicate your Member State’s corresponding level: | Regarding Member States’s planning to test the financial resources for contingency funding to respond to health threats, please indicate your Member State’s corresponding level: | Indicator 1-5 or N/A |
| A.2.1 | level | Indicator 1-5 or N/A | |
| A.2.1 | Member State cannot answer the question [at central state level] | N/A | Indicator 1-5 or N/A |
| A.2.1 | There are no plans to conduct tests of financial resources for contingency funding for response to health threats in the next 3 years | 1 | Indicator 1-5 or N/A |
| A.2.1 | There are plans to conduct tests of financial resources for contingency funding for response to health threats in the next 3 years but this is on an ad hoc basis | 2 | Indicator 1-5 or N/A |
| A.2.1 | There are plans to conduct tests of financial resources for contingency funding for response to health threats and this is to be conducted on a regular basis | 3 | Indicator 1-5 or N/A |
| A.2.1 | Tests of financial resources for contingency funding for response to health threats have been and continue to be conducted on a regular basis | 4 | Indicator 1-5 or N/A |
| A.2.1 | As per level 4, and, in addition, recommendations from the tests have been implemented and corresponding plans have been reviewed and revised | 5 | Indicator 1-5 or N/A |
| A.2.1 | — Additional comments: Your Member State cannot answer this question at the central state level, due to governance and legislative frameworks? (yes) In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) If yes, please advise if at central level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges If not, please explain: | — Additional comments: Your Member State cannot answer this question at the central state level, due to governance and legislative frameworks? (yes) In this case, please indicate if national level recommendations/guidelines are sent to regional authorities (yes/no) If yes, please advise if at central level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges If not, please explain: | Indicator 1-5 or N/A |
| A.2.2 | Does the Ministry of Health and Ministry of Finance of your Member State have dedicated procedures for the coordination of policies and activities in the case of a public health emergency? (yes/no/other) — If yes, please elaborate: (e.g., regular meetings, joint task force orworking group, guidelines, and regulatory measures, etc.) — If other, please describe: | Does the Ministry of Health and Ministry of Finance of your Member State have dedicated procedures for the coordination of policies and activities in the case of a public health emergency? (yes/no/other) — If yes, please elaborate: (e.g., regular meetings, joint task force orworking group, guidelines, and regulatory measures, etc.) — If other, please describe: | N/A |
3. Laboratory
| Question | Question | Indicator | |
| A.3.1 | Please indicate your Member State’s corresponding level in relation to the scaling up the laboratory testing capacity in the event of a public health emergency: | Please indicate your Member State’s corresponding level in relation to the scaling up the laboratory testing capacity in the event of a public health emergency: | Indicator 1-5 |
| A.3.1 | Level | Indicator 1-5 | |
| A.3.1 | There is no plan and organisation2 for scaling up the laboratory testing capacity in the event of a public health emergency | 1 | Indicator 1-5 |
| A.3.1 | A plan and organisation for scaling up the laboratory testing capacity in the event of a public health emergency is being developed | 2 | Indicator 1-5 |
| A.3.1 | There is a plan and organisation for scaling up the laboratory testing capacity in the event of a public health emergency, but the plan has not been tested in the last 3 years | 3 | Indicator 1-5 |
| A.3.1 | There is a plan and organisation for scaling up the laboratory testing capacity in the event of a public health emergency and this plan has been tested in a stress test in the last 3 years | 4 | Indicator 1-5 |
| A.3.1 | As per level 4 and, in addition, the system has been revised accordingly | 5 | Indicator 1-5 |
| A.3.1 | — Additional comments: | — Additional comments: | Indicator 1-5 |
| A.3.2 | Please indicate your Member State’s corresponding level regarding implementation of new nucleic acid amplification-based tests (NAATs) and adapted associated laboratory systems in the event of a novel pathogen emergence with pandemic potential: | Please indicate your Member State’s corresponding level regarding implementation of new nucleic acid amplification-based tests (NAATs) and adapted associated laboratory systems in the event of a novel pathogen emergence with pandemic potential: | Indicator 1-5 |
| A.3.2 | Level | Indicator 1-5 | |
| A.3.2 | In the context of my Member State, it would not be possible to implement new NAATs and adapt associated laboratory systems within 6 months. | 1 | Indicator 1-5 |
| A.3.2 | > 3 – 6 months | 2 | Indicator 1-5 |
| A.3.2 | > 1 – 3 months | 3 | Indicator 1-5 |
| A.3.2 | 2 – 4 weeks | 4 | Indicator 1-5 |
| A.3.2 | < 2 weeks | 5 | Indicator 1-5 |
| A.3.2 | — Additional comments: | — Additional comments: | Indicator 1-5 |
| A.3.3 | Please indicate you Member State’s corresponding level, in an event of a public health emergency with pandemic potential requiring large-scale testing | Please indicate you Member State’s corresponding level, in an event of a public health emergency with pandemic potential requiring large-scale testing | Indicator 1-5 or N/A |
| A.3.3 | Level | Indicator 1-5 or N/A | |
| A.3.3 | Your Member State cannot answer due to difficulties to quantify NAAT capacity according to these levels | N/A | Indicator 1-5 or N/A |
| A.3.3 | In an event of a public health emergency and where a validated NAAT is available, it would be possible to scale up diagnostic NAAT testing services to a weekly sample testing capacity corresponding to up to 0,01 % of the population in my Member State | 1 | Indicator 1-5 or N/A |
| A.3.3 | In an event of a health emergency and where a validated NAAT is available, it would be possible to scale up diagnostic NAAT testing services to a weekly sample testing capacity corresponding to 0,01-0,1 % of the population in my Member State | 2 | Indicator 1-5 or N/A |
| A.3.3 | In an event of a health emergency and where a validated NAAT is available, it would be possible to scale up diagnostic NAAT testing services to a weekly sample testing capacity corresponding to 0,1-1 % of the population in my Member State | 3 | Indicator 1-5 or N/A |
| A.3.3 | In an event of a health emergency and where a validated NAAT is available, it would be possible to scale up diagnostic NAAT testing services to a weekly sample testing capacity corresponding to 1-2 % of the population in my Member State | 4 | Indicator 1-5 or N/A |
| A.3.3 | In an event of a health emergency and where a validated NAAT is available, it would be possible to scale up diagnostic NAAT testing services to a weekly sample testing capacity corresponding to > 2 % of the population in my Member State | 5 | Indicator 1-5 or N/A |
| A.3.3 | — If N/A, please quantify NAAT capacity according to your own proposal: — Additional comments: | — If N/A, please quantify NAAT capacity according to your own proposal: — Additional comments: | Indicator 1-5 or N/A |
| A.3.4 | Does your Member State have access to additional sources of laboratory capacity for diagnostic services in an event where an increased capacity is needed (e.g. research or veterinary laboratories, etc.)? (yes/no/other) — If yes, please advise if this is by formal agreement or on an ad hoc basis. — If other, please describe: | Does your Member State have access to additional sources of laboratory capacity for diagnostic services in an event where an increased capacity is needed (e.g. research or veterinary laboratories, etc.)? (yes/no/other) — If yes, please advise if this is by formal agreement or on an ad hoc basis. — If other, please describe: | N/A |
| A.3.5 | Does your Member State have the capacity for reporting laboratory testing results for national surveillance via an electronic reporting system? (yes/no/other) — If yes, is this reporting system capable of managing scaled up testing information? (yes/no) — If yes, is this reporting system capable of integrating input from different sources of laboratory capacities (e.g., research, hospitals, commercial or veterinary laboratories, etc.)? (yes/no) — If other, please describe: | Does your Member State have the capacity for reporting laboratory testing results for national surveillance via an electronic reporting system? (yes/no/other) — If yes, is this reporting system capable of managing scaled up testing information? (yes/no) — If yes, is this reporting system capable of integrating input from different sources of laboratory capacities (e.g., research, hospitals, commercial or veterinary laboratories, etc.)? (yes/no) — If other, please describe: | N/A |
| A.3.6 | Please indicate if your Member State has access to high-containment laboratories i.e. biosafety level 3 or 4 laboratories: Does your Member State have access to a biosafety level 3 laboratory? (yes/no/other) — If no, does your Member State have a formal agreement with another EU/EEA country for this service? (yes/no) — If other, please describe: Does your Member State have access to a biosafety level 4 laboratory (yes/no/other) — If no, does your country have a formal agreement with another EU/EEA Member State for this service? (yes/no) — If other, please describe: In accordance with Article 346(1) of the Treaty, no Member State is obliged to supply information the disclosure of which it considers contrary to the essential interests of its security | Please indicate if your Member State has access to high-containment laboratories i.e. biosafety level 3 or 4 laboratories: Does your Member State have access to a biosafety level 3 laboratory? (yes/no/other) — If no, does your Member State have a formal agreement with another EU/EEA country for this service? (yes/no) — If other, please describe: Does your Member State have access to a biosafety level 4 laboratory (yes/no/other) — If no, does your country have a formal agreement with another EU/EEA Member State for this service? (yes/no) — If other, please describe: In accordance with Article 346(1) of the Treaty, no Member State is obliged to supply information the disclosure of which it considers contrary to the essential interests of its security | N/A |
| A.3.7 | Does your Member State have the capacity for characterization of a novel pathogen by Next Generation Sequencing (NGS)? (yes/no/other) — If yes, are NGS data for national surveillance reported via an electronic reporting system? (yes/no) — If no, does your country have an arrangement with another Member State? (yes/no). — If yes, please indicate the Member State: — If other, please describe: | Does your Member State have the capacity for characterization of a novel pathogen by Next Generation Sequencing (NGS)? (yes/no/other) — If yes, are NGS data for national surveillance reported via an electronic reporting system? (yes/no) — If no, does your country have an arrangement with another Member State? (yes/no). — If yes, please indicate the Member State: — If other, please describe: | N/A |
| A.3.8 | Does your Member State have a facility dedicated to validating newly introduced devices for the diagnosis of the novel pathogen? (yes/no/other) — If other, please describe: | Does your Member State have a facility dedicated to validating newly introduced devices for the diagnosis of the novel pathogen? (yes/no/other) — If other, please describe: | N/A |
4. Surveillance
| Question | Question | Indicator | |
| A.4.1 | Does your Member State’s surveillance system for acute respiratory infections cover all healthcare levels? (yes/no/other) — If other, please describe: | Does your Member State’s surveillance system for acute respiratory infections cover all healthcare levels? (yes/no/other) — If other, please describe: | N/A |
| A.4.2 | Are the surveillance systems for Acute Respiratory Infection (ARI), Influenza -Like Illness (ILI) and Severe Acute Respiratory Infections (SARI) automated3 in your Member State? (yes/no/other) — If other, please describe: | Are the surveillance systems for Acute Respiratory Infection (ARI), Influenza -Like Illness (ILI) and Severe Acute Respiratory Infections (SARI) automated3 in your Member State? (yes/no/other) — If other, please describe: | N/A |
| A.4.3 | Would your Member State’s surveillance system for respiratory infections be able to scale up during a pandemic (i.e., to increase the number of reporting sites, the breath of data collected, the timeliness of reporting, etc.)? (yes/no/other) — If other, please describe: | Would your Member State’s surveillance system for respiratory infections be able to scale up during a pandemic (i.e., to increase the number of reporting sites, the breath of data collected, the timeliness of reporting, etc.)? (yes/no/other) — If other, please describe: | N/A |
| A.4.4 | Is your Member State able to monitor the following indicators on an ongoing basis and for the whole country’s territory, during a public health emergency (i.e. taking into account expanded capacities and/or new settings)? | Is your Member State able to monitor the following indicators on an ongoing basis and for the whole country’s territory, during a public health emergency (i.e. taking into account expanded capacities and/or new settings)? | N/A |
| A.4.4 | yes/no | N/A | |
| A.4.4 | Hospital bed capacity | N/A | |
| A.4.4 | Hospital intensive care units’ capacity | N/A | |
| A.4.4 | Hospital emergency rooms capacity | N/A | |
| A.4.4 | Hospital utilisation | N/A | |
| A.4.4 | Testing capacity | N/A | |
| A.4.4 | Contact tracing capacity | N/A | |
| A.4.4 | Other, please describe | N/A | |
| A.4.4 | — Additional comments: | — Additional comments: | N/A |
| A.4.5 | Does your country have a wastewater monitoring system in place for respiratory pathogens? (yes/no/other) — If other, please describe: | Does your country have a wastewater monitoring system in place for respiratory pathogens? (yes/no/other) — If other, please describe: | N/A |
| A.4.6 | Does your country have plans and infrastructures for timely and ongoing assessment of a pandemic threat, i.e., for assessing: | Does your country have plans and infrastructures for timely and ongoing assessment of a pandemic threat, i.e., for assessing: | N/A |
| A.4.6 | yes/no | N/A | |
| A.4.6 | Transmissibility, route of transmission, effective reproduction number | N/A | |
| A.4.6 | Severity | N/A | |
| A.4.6 | Immunologic correlates of protection | N/A | |
| A.4.6 | Vaccine effectiveness | N/A | |
| A.4.6 | Epidemic trajectories and impact through mathematical modelling | N/A | |
| A.4.6 | Other, please specify: | Other, please specify: | N/A |
| A.4.6 | — Additional comments: | — Additional comments: | N/A |
5. Human resources
| Question | Question | Question | Question | Question | Question | Indicator | |
| A.5.1 | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | In the event of a public health emergency regarding a potential surge in demand of human resources, please indicate your Member State’s level: | Indicator 1-5 or N/A |
| A.5.1 | Hospital services | Outpatient primary care services | Laboratory services (outside of hospitals) | Other public health services | Indicator 1-5 or N/A | ||
| A.5.1 | N/A | Member State cannot answer the question at central state level | Indicator 1-5 or N/A | ||||
| A.5.1 | Level 1 | There is no mechanism to ensure a surge in human resources in the event of a public health emergency | Indicator 1-5 or N/A | ||||
| A.5.1 | Level 2 | There is no mechanism to ensure a surge in human resources in the event of a public health emergency but there is a plan to work on a strategy to have it in the coming 3 years | Indicator 1-5 or N/A | ||||
| A.5.1 | Level 3 | There is a mechanism to ensure a surge in human resource in the event of a public health emergency, but it is not a structured operational instrument nor is it routinely updated | Indicator 1-5 or N/A | ||||
| A.5.1 | Level 4 | There is a mechanism to ensure a surge in human resource in the event of a public health emergency which comprises a structured operational instrument that is routinely updated and participants are periodically trained | Indicator 1-5 or N/A | ||||
| A.5.1 | Level 5 | As per level 4 and, in addition, this mechanism is tested to ensure its functioning | Indicator 1-5 or N/A | ||||
| A.5.1 | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | — Additional comments: Your country cannot answer this question at the central state level due to governance and legislative frameworks? (yes) — In this case, please indicate whether national level recommendations/guidelines are sent to regional authorities (yes/no) — If yes, please advise if at national level you know if these recommendations/guidelines are implemented at regional level and whether there are gaps or challenges identified: — If not, please, explain | Indicator 1-5 or N/A |
| A.5.2 | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | Please advise if regions within your Member State have agreements to receive/exchange human resource support in the health sector in case of need? (yes/no/other) — If other, please describe: | N/A |
6. Health emergency management
Management of health emergency response
Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.
This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence.
EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.